Amerise Biosciences files Reg 29(2) notice on share acquisition by Snehjeev Ventures and PACs

What Amerise Biosciences announced

On 9 July 2026 Amerise Biosciences Ltd (BSE: 531681) filed a disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The filing informs the market that Snehjeev Ventures Pvt Ltd and persons acting in concert (PACs) have acquired a substantial block of Amerise shares. No further details on the size of the stake or the consideration paid were provided in the notice.

Details of the Reg 29(2) filing

Regulation 29(2) obliges any person or entity that acquires shares crossing the 1 % threshold, or any subsequent increase that brings the holding to 5 % or higher, to disclose the acquisition to the stock exchange within two trading days. The purpose is to ensure transparency and give existing shareholders timely information about changes in control.

The filing lists two categories of acquirers:

• Snehjeev Ventures Pvt Ltd – a private limited company.
• Persons Acting in Concert (PACs) – individuals or entities that have agreed to act together in exercising voting rights.

The notice does not specify the exact percentage of shares acquired, the monetary value of the transaction, or the intended purpose of the purchase. It merely satisfies the statutory requirement to inform the market of a “substantial acquisition”.

Key facts at a glance

Why this matters for investors

The disclosure signals that a new shareholder group now holds a material interest in Amerise Biosciences. While the exact size of the holding is unknown, any acquisition that triggers Reg 29(2) typically indicates a stake of at least 1 % and possibly higher. If the combined holding reaches 5 % or more, the acquirers must make a public offer to all other shareholders under SEBI’s takeover code. Until the exact percentage is known, investors should monitor subsequent filings for updates on shareholding patterns and any potential offer or board changes.

Conclusion

Amerise Biosciences has complied with SEBI’s disclosure requirements by reporting that Snehjeev Ventures Pvt Ltd and associated PACs have acquired a substantial shareholding. The filing does not reveal the magnitude of the stake or the transaction value, leaving investors to await further disclosures that will clarify the impact on the company’s ownership structure and any regulatory steps that may follow.